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Hypofractionated 3D conformal radiotherapy in prostate cancer patients. Toxicity and outcome at 2 years of
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Purpose. To evaluate Biochemical-Free Survival (bNED) and acute and late toxicity in prostate cancer patients treated with
Hipofractionated 3D Conformal Radiotherapy.
Methods and materials. Clinical records of the ﬁrst 12 consecutive T1-T2 N0M0 prostate cancer patients treated with hypofrac-
tionated 3D Conformal Radiotherapy (50Gy in 16 fractions within 3–4 week) in our department from 2008 had been reviewed.
Gastrointestinal (GI) and Genitourinary (GU) acute toxicities were evaluated by the RTOG/EORTC scale. Late toxicity was evalu-
ated by the modiﬁed Late Effect in Normal tissue Subjective Objective Management Analytic (LENT/SOMA). bNED was deﬁned by
the ASTRO consensus deﬁnition. Patient’s mean age was 73 years (range 62–85 years). Mean PSA pretreatment was 29.03 (range
4.5–200 mg/dl). Stage T1c, 10 (83%); T2c, 2 (17%); Gleason 2–6, 10 (83%); Gleason 7, 2 (17%). Pretreatment PSA<10, 7 (58%); PSA
10–20, 4 (33%); PSA>20, 1 (8%). Median follow-up was 32 months (range 23–45 months).
Results. 2 years bNED survivalwas associatedwith pretreatment PSA level and Stage andGleason score. Patientswere grouped into
Low (Stage T1–T2a; PSA<10; Gleason<6), 7 (58%); Intermediate (T2b; PSA 10 to 20; Gleason 7), 4 (33%); High (T2c; PSA>20; Gleason
8 to10), 1 (8%) risk groups. The bNED was 92%. Only high risk 1 patient, after 38 months following has a relapse biochemical. GU
acute toxicity was: Asymptomatic, 4 (33%); Grade (G) I, 4 (33%), GII, 1 (8%); GIV, 3 (25%) and GI Acute Toxicity was: Asymptomatic,
10 (84%); GI, 1 (8%). GI Late toxicity was: Asymptomatic, 11 (91.6%); GI, 1(8%) and GU Late Toxicity was: Asymptomatic, 3 (25%);
GI, 5 (42%); GII, 3 (25%); GIII, 3 (25%), GIV, 0 (0%). Sexual Dysfunction: 4 (33%). Radiotherapy was delivered to a planning target
volume with 4–6 ﬁeld conformal technique to a dose of 50Gy en 16 daily fractions.
Conclusions. 3D Hypofractioned Radiotherapy is well tolerated and its side effects and outcome are similar those of 3DCRT. In
addition, hypofractionation offers a reduction in fraction number and produced attractive cost and increased convenience for
patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.486
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Introduction. Moderate hypofractionated scheme of low-risk prostate adenocarcinoma radiation treatment is a suitable choice for
shortening treatment lengthwhile keeping acute toxicity low. IMRTallows simultaneous treatment of several volumes at different
dose levels. This makes IMRT a good option for intermediate and high-risk prostate patients to integrate the hypofractionated
prostate boost, reducing the overall treatment length and maintaining a standard fractionation for seminal vesicles and pelvic
lymph node.
Objectives. To demonstrate that hypofractionated treatment of prostate adenocarcinoma beneﬁts all risk groups, using the con-
comitant boost for intermediate and high risk patients.
Methods. In October 2011 our department implemented moderate hypofractionation of low-risk prostate patients. The course
of radiation therapy reduced to 27 fractions. To include intermediate and high-risk patients to this scheme, a pelvic lymph
node with simultaneous prostate boost IMRT technique was devised. Treatment is daily image guided with CBCT for accurate
prostate localization. Exhaustive training of the RTTs on CBCT image was needed. An empty rectum, ﬁlled bladder protocol was
implemented. The hypofractionated scheme comprises a prostate fraction dose of 2.6Gy, 27 fractions, summing up 82Gy, 2Gy/fr
equivalent. Seminal vesicles and pelvic lymph nodes fractionation was calculated to obtained the isoefect dose in 27 fractions.
As a result, 2.25Gy/fraction to seminal vesicles PTV and 1.8Gy/fraction to pelvic lymph nodes PTV were prescribed.
Results. 26 patients underwent the concomitant boost technique, 11 involving seminal vesicles plus pelvic lymph nodes irra-
diation and 15 seminal vesicles. Only one patient showed gastrointestinal and genitourinary G3 toxicities, requiring urinary
catheterization the last day of treatment. The rest of patients showed similar gastrointestinal and genitourinary G1 toxicities as
those described for the standard 2Gy/fraction scheme.
Conclusions. Intermediate and high-risk prostate patients beneﬁt from the image guided IMRT hypofractionated concomitant
boost technique. Affordable toxicity at organs at risk, accurate dose administration and shorter overall treatment length are the
main advantages.
http://dx.doi.org/10.1016/j.rpor.2013.03.487
